Table of Contents

2018-2023 Global Edaravone Injection Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Edaravone Injection Consumption 2013-2023
  • 2.1.2 Edaravone Injection Consumption CAGR by Region
• 2.2 Edaravone Injection Segment by Type
  • 2.2.1 20ml
  • 2.2.2 100ml
• 2.3 Edaravone Injection Consumption by Type
  • 2.3.1 Global Edaravone Injection Consumption Market Share by Type (2013-2018)
  • 2.3.2 Global Edaravone Injection Revenue and Market Share by Type (2013-2018)
  • 2.3.3 Global Edaravone Injection Sale Price by Type (2013-2018)
• 2.4 Edaravone Injection Segment by Application
  • 2.4.1 Hospital
  • 2.4.2 Pharmacy
• 2.5 Edaravone Injection Consumption by Application
  • 2.5.1 Global Edaravone Injection Consumption Market Share by Application (2013-2018)
  • 2.5.2 Global Edaravone Injection Value and Market Share by Application (2013-2018)
  • 2.5.3 Global Edaravone Injection Sale Price by Application (2013-2018)

3 Global Edaravone Injection by Players

• 3.1 Global Edaravone Injection Sales Market Share by Players
  • 3.1.1 Global Edaravone Injection Sales by Players (2016-2018)
  • 3.1.2 Global Edaravone Injection Sales Market Share by Players (2016-2018)
• 3.2 Global Edaravone Injection Revenue Market Share by Players
  • 3.2.1 Global Edaravone Injection Revenue by Players (2016-2018)
  • 3.2.2 Global Edaravone Injection Revenue Market Share by Players (2016-2018)
• 3.3 Global Edaravone Injection Sale Price by Players
• 3.4 Global Edaravone Injection Manufacturing Base Distribution, Sales Area, Product Types by Players
  • 3.4.1 Global Edaravone Injection Manufacturing Base Distribution and Sales Area by Players
  • 3.4.2 Players Edaravone Injection Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Edaravone Injection by Regions

• 4.1 Edaravone Injection by Regions
  • 4.1.1 Global Edaravone Injection Consumption by Regions
  • 4.1.2 Global Edaravone Injection Value by Regions
• 4.2 Americas Edaravone Injection Consumption Growth
• 4.3 APAC Edaravone Injection Consumption Growth
• 4.4 Europe Edaravone Injection Consumption Growth
• 4.5 Middle East & Africa Edaravone Injection Consumption Growth

5 Americas

• 5.1 Americas Edaravone Injection Consumption by Countries
  • 5.1.1 Americas Edaravone Injection Consumption by Countries (2013-2018)
  • 5.1.2 Americas Edaravone Injection Value by Countries (2013-2018)
• 5.2 Americas Edaravone Injection Consumption by Type
• 5.3 Americas Edaravone Injection Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Edaravone Injection Consumption by Countries
  • 6.1.1 APAC Edaravone Injection Consumption by Countries (2013-2018)
  • 6.1.2 APAC Edaravone Injection Value by Countries (2013-2018)
• 6.2 APAC Edaravone Injection Consumption by Type
• 6.3 APAC Edaravone Injection Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Edaravone Injection by Countries
  • 7.1.1 Europe Edaravone Injection Consumption by Countries (2013-2018)
  • 7.1.2 Europe Edaravone Injection Value by Countries (2013-2018)
• 7.2 Europe Edaravone Injection Consumption by Type
• 7.3 Europe Edaravone Injection Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Edaravone Injection by Countries
  • 8.1.1 Middle East & Africa Edaravone Injection Consumption by Countries (2013-2018)
  • 8.1.2 Middle East & Africa Edaravone Injection Value by Countries (2013-2018)
• 8.2 Middle East & Africa Edaravone Injection Consumption by Type
• 8.3 Middle East & Africa Edaravone Injection Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
• 10.2 Edaravone Injection Distributors
• 10.3 Edaravone Injection Customer

11 Global Edaravone Injection Market Forecast

• 11.1 Global Edaravone Injection Consumption Forecast (2018-2023)
• 11.2 Global Edaravone Injection Forecast by Regions
  • 11.2.1 Global Edaravone Injection Forecast by Regions (2018-2023)
  • 11.2.2 Global Edaravone Injection Value Forecast by Regions (2018-2023)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Edaravone Injection Forecast by Type
• 11.8 Global Edaravone Injection Forecast by Application

12 Key Players Analysis

• 12.1 Mitsubishi Tanabe Pharma
  • 12.1.1 Company Details
  • 12.1.2 Edaravone Injection Product Offered
  • 12.1.3 Mitsubishi Tanabe Pharma Edaravone Injection Sales, Revenue, Price and Gross Margin (2016-2018)
  • 12.1.4 Main Business Overview
  • 12.1.5 Mitsubishi Tanabe Pharma News

...

13 Research Findings and Conclusion

Edaravone, sold as under the brand names Radicava and Radicut, is an intravenous medication used to help with recovery following a stroke[1] and to treat amyotrophic lateral sclerosis (ALS).

According to this study, over the next five years the Edaravone Injection market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2017. In particular, this report presents the global market share (sales and revenue) of key companies in Edaravone Injection business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Edaravone Injection market by product type, application, key manufacturers and key regions and countries.

This study considers the Edaravone Injection value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2013 to 2018, in Section 2.3; and forecast to 2024 in section 11.7.
20ml
100ml
Segmentation by application: breakdown data from 2013 to 2018, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmacy

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Mitsubishi Tanabe Pharma
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Edaravone Injection consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2024.
To understand the structure of Edaravone Injection market by identifying its various subsegments.
Focuses on the key global Edaravone Injection manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Edaravone Injection with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Edaravone Injection submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.